Literature DB >> 12208601

Analysis of Neisseria lactamica antigens putatively implicated in acquisition of natural immunity to Neisseria meningitidis.

G Troncoso1, S Sánchez, M T Criado, C M Ferreirós.   

Abstract

Sera from healthy human volunteers, patients convalescent from meningococcal meningitis, and mice immunized with outer membrane proteins from Neisseria meningitidis and Neisseria lactamica strains were used to analyze and identify antigens cross-reactive to both neisserial species. All classes of meningococcal proteins except class 1 (PorA) and class 5 cross-reacted with N. lactamica proteins and two other proteins of 65 and 55 kDa (an iron-regulated protein). Results obtained with the mouse sera demonstrate that cross-reactive antibodies can be elicited by either N. meningitidis or N. lactamica. These results support the suggestion that N. lactamica contributes to the development of natural immunity against N. meningitidis during the first years of life. The use of vaccines containing proteins other than PorA could interfere in colonization of mucosal surfaces by N. lactamica, hampering the natural mechanisms of immunity acquisition in humans. Only convalescent sera reacted with the 55 and 65 kDa proteins, which suggests that they might be relevant for pathogenicity. Copyright 2002 Federation of European Microbiological Societies

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12208601     DOI: 10.1111/j.1574-695X.2002.tb00597.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  9 in total

1.  Neisseria lactamica antigens complexed with a novel cationic adjuvant.

Authors:  Emanuelle B Gaspar; Andreza S Rosetti; Nilton Lincopan; Elizabeth De Gaspari
Journal:  Hum Vaccin Immunother       Date:  2013-01-07       Impact factor: 3.452

2.  Immunization with live Neisseria lactamica protects mice against meningococcal challenge and can elicit serum bactericidal antibodies.

Authors:  Yanwen Li; Qian Zhang; Megan Winterbotham; Eva Mowe; Andrew Gorringe; Christoph M Tang
Journal:  Infect Immun       Date:  2006-09-11       Impact factor: 3.441

Review 3.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

4.  The PorB porin from commensal Neisseria lactamica induces Th1 and Th2 immune responses to ovalbumin in mice and is a potential immune adjuvant.

Authors:  Xiuping Liu; Lee M Wetzler; Paola Massari
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641

Review 5.  Mechanisms in Neisseria meningitidis for resistance against complement-mediated killing.

Authors:  Elisabeth Kugelberg; Bridget Gollan; Christoph M Tang
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

6.  Variation in the Neisseria lactamica porin, and its relationship to meningococcal PorB.

Authors:  Julia S Bennett; Martin J Callaghan; Jeremy P Derrick; Martin C J Maiden
Journal:  Microbiology (Reading)       Date:  2008-05       Impact factor: 2.777

7.  Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers.

Authors:  Timo Vesikari; Aino Forstén; Dominique Boutriau; Véronique Bianco; Marie Van der Wielen; Jacqueline M Miller
Journal:  Hum Vaccin Immunother       Date:  2012-10-02       Impact factor: 3.452

Review 8.  Exploring Host-Commensal Interactions in the Respiratory Tract.

Authors:  Sudhanshu Shekhar; Karl Schenck; Fernanda Cristina Petersen
Journal:  Front Immunol       Date:  2018-01-17       Impact factor: 7.561

9.  Antibodies Reactive to Commensal Streptococcus mitis Show Cross-Reactivity With Virulent Streptococcus pneumoniae Serotypes.

Authors:  Sudhanshu Shekhar; Rabia Khan; Daniela M Ferreira; Elena Mitsi; Esther German; Gro Herredsvela Rørvik; Dag Berild; Karl Schenck; Keehwan Kwon; Fernanda Petersen
Journal:  Front Immunol       Date:  2018-04-16       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.